Early Notification and Brand Change Moxifloxacin Injection
As advised via PHARMAC Tender Results of 30 September 2019 there is to be a change in the listing and future sole supply of moxafloxacin Injection.
New listing from 1 November 2019 (HML ONLY)
Moxafloxacin Kabi Inj 1.6 mg per ml, 250 ml bottle Pharmacode TBA Schedule price $39.00
Avelox IV 400 Inj 1.6 mg per ml, 250 ml bottle Pharmacode 2475162 Schedule price $70.00
HSS (Hospital Supply Status) commences 1 April 2020.
As of the date of this notification ProPharma / PWR cannot accept Avelox IV 400 for credit under any circumstances.
We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.